N/A N=28 Reminiscence Technology Balance and Mobility
Adults Living in Long Term Care
Primary: Number of Participants Recruited — 14; 14 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=50 Colesevelam Versus Placebo in the Treatment of Nonalcoholic Steatohepatitis
Nonalcoholic Steatohepatitis
Primary: The Primary Outcome Will be Improvement in Hepatic Steatosis by Liver MRI — 17.9; 14.2 % of fat
Phase 4 N=382 A Study of Immune Phenotype Biomarkers in Patients With Relapsing Multiple Sclerosis (RMS) After Treatment With 0.5mg Fingolimod
Relapsing Multiple Sclerosis
Primary: Change From Baseline to Month 6 in CD4+ Naive T Cells (CCR7+ CD45RA+) — 404.4; 3.4; 7.6; 4.8 cells/uL
N/A N=67 Pilot Prospective CGM Quality Improvement (QI) Project in Pregnancy
Diabetes Mellitus, Type I
Primary: Changes in Glucose Variability — 7.5; 7.3; 52.8; 59.8 % time spent in range
Phase 4 N=70 Ondansetron for Bipolar Disorder and Alcohol Use Disorders
Bipolar Disorder · Alcohol Use Disorder · Dual Diagnosis
Primary: Hamilton Rating Scale for Depression (HAMD) — 13.77; 14.23; 8.52; 8.86 score on a scale
Phase 2 N=9 Erlotinib, Paclitaxel, and Carboplatin Combined With Radiation Therapy for Stage III Non-Small Cell Lung Cancer
Lung Cancer
Primary: Maximum Tolerated Dose of Erlotinib Hydrochloride (Phase I) — 150 mg daily
Phase 3 N=476 A Study Comparing Diclofenac Sodium Gel 3% to Solaraze® (Diclofenac Sodium) Gel 3% in the Treatment of Actinic Keratosis
Actinic Keratosis
Primary: Percentage of Patients With 100% Clearance of All AK Lesions Within the Treatment Area Assessed at Day 90 — 31; 32; 7; 108 Participants — p=0.0010
N/A N=150 txt2protect: Using Text Messaging to Increase HPV Vaccination Among Young Sexual Minority Men
Human Papillomavirus
Primary: Retention — 63; 69 Participants — p=.601
N/A N=24 Adhesive Tape Trauma Evaluation of a New Gentle Tape in Healthy Infant Subjects
Skin (FLACC Scores of Test Subjects) After Tape Removal
Primary: The Face, Legs, Activity, Cry, Consolability (FLACC) Score. — 0.29 units on a scale
Phase 2 N=834 A Study to Evaluate the Efficacy and Safety of MEDI0382 in the Treatment of Overweight and Obese Subjects With Type 2 Diabetes
Diabetes Mellitus, Type 2
Primary: Change in HbA1c — -0.18; -1.01; -1.22; -1.09 percentage — p=<0.001
Phase 3 N=403 A Long-term Extension Study for the Phase 3 Study of Nalmefene (339-14-001) in Patients With Alcohol Dependence
Alcohol Dependence
Primary: Number of Participants With Adverse Events — 96; 67; 141 Number of participants
N/A N=162 Comparison of Intravascular Uptake and Pain Perception During Epidural Injection Using 22 Gauge vs 25 Gauge Needle
Pain · Needle Injury
Primary: Intravascular Uptake — 5.9; 7.1 percentage of total number of needle
Phase 2 N=397 Efficacy and Safety of a New Chewable Versus the Swallowable Tablet of Mebendazole Against Hookworm
Hookworm Infections
Primary: Geometric Mean Egg Reduction Rate (ERR) of the Two Formulations of Mebendazole Against Hookworm — 68.5; 70.8 percentage change in hookworm egg counts
Phase 4 N=13 Collection of Blood Samples From Patients With Relapsing MS Who Developed ITP After Receiving Lemtrada
Multiple Sclerosis
Primary: Number of Participants Who Provided Whole Blood Samples for DNA Extraction and Analysis — 12; 12; 12; 12 Participants
Phase 1 N=22 IL-2 Expressing, Attenuated Salmonella Typhimurium in Unresectable Hepatic Spread
Cancer of the Liver · Liver Cancer · Hepatoma
Primary: Number of Participants With Dose Limiting Events to Determine the Maximum Tolerated Dose (MTD) of Salmonella Typhimurium — 0; 0; 0; 0 Participants